Long-term Efficacy of Canakinumab in the Treatment of Schnitzler Syndrome

CAPSULE SUMMARY: This 4-year long-term study confirms that canakinumab treatment effectively reduces the clinical signs and symptoms of Schnitzler syndrome, decreases inflammatory markers, and improves overall quality of life. However, canakinumab therapy requires close monitoring for infections.